{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-085588","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2025-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.180214+00:00","generated_at":"2026-05-19T10:29:12.636647+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Eledon shareholders approve increase in authorized common shares to 300M","bullets":["Shareholders approved increase in authorized common stock from 200M to 300M shares (40.79M for, 0.49M against).","Approved amendment to extend officer exculpation protection to fullest extent under Delaware law (30.04M for, 1.29M against).","Elected Class II directors Keith Katkin, Allan Kirk, and John McBride for three-year terms ending 2028.","Ratified Deloitte & Touche as independent auditor for FY2025 (41.31M for, 36k against).","Authorized share increase and officer exculpation amendments became effective June 10, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-085588","json":"https://secwatch.observer/filing/0000950170-25-085588.json","markdown":"https://secwatch.observer/filing/0000950170-25-085588.md","text":"https://secwatch.observer/filing/0000950170-25-085588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025085588/0000950170-25-085588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025085588/eldn-20250610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T10:29:12.636647+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03d1533b1da2dfa71cbb4b0d85e23ed80a87a7ac","claim":"Eledon Pharmaceuticals, Inc.: Extended exculpation protection to officers to the fullest extent permitted by Delaware law.","evidence_excerpt":"a Certificate of Amendment (the “Officer Exculpation Amendment”) to amend the Certificate of Incorporation to extend exculpation protection to officers, to the fullest extent permitted by Delaware law","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025085588/0000950170-25-085588-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"1694dda89f2305c06b024f1dbd7f85afc2ee4939","claim":"Eledon Pharmaceuticals, Inc.: Increased authorized shares of common stock from 200,000,000 to 300,000,000.","evidence_excerpt":"the Company filed the following with the Secretary of State of the State of Delaware: • a Certificate of Amendment (the “Authorized Share Increase Amendment”) to the Company’s Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) to amend the Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000 shares","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025085588/0000950170-25-085588-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}